A prospective observational study of screening for MSI status in unresectable chemo-naive advanced gastric cancer:WJOG13320GPS
Not Applicable
- Conditions
- unresectable advanced gastric cancer
- Registration Number
- JPRN-UMIN000040366
- Lead Sponsor
- West Japan Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
Not provided
Exclusion Criteria
1)Having concomitant active malignancies. 2)Requiring systemic corticosteroid or immunosuppressant. 3)History of prior anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4 antibody, or any other antibody which specifically targets T-cell co-stimulation or checkpoint pathways. 4)Inappropriate judged by the investigators.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The proportion of patients with MSI-high in chemotherapy-naive gastric cancer
- Secondary Outcome Measures
Name Time Method 1) Clinicopathological features of advanced or recurrent gastric cancer with MSI-high status 2) Turn-around-time of MSI test 3) Success rate of MSI test